Latest news with #MorningStarLaboratories
Business Upturn
7 days ago
- Health
- Business Upturn
SmartVascular Dx™ Test Elevates Vascular Risk Detection in the Northeast & Partnership with MOMS
IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now more accessible than ever for patients in the northeastern United States. We are proud to share that we have been included in the Medicare fee schedule, allowing us to offer national Medicare coverage along with our new partnerships with CareSource and HealthPartners. The SmartVascular Dx test provides a significant clinical advantage by accurately detecting vascular inflammation, a crucial factor in assessing cardiovascular risk. In a healthcare landscape increasingly focused on preventive strategies, this test supports early intervention, aligning seamlessly with the commitment to proactive healthcare in the region. We encourage physicians in the northeastern United States to seize this opportunity to offer the SVDx test to their patients. By identifying vascular risks earlier, healthcare providers can implement timely interventions, ultimately saving lives and improving health outcomes. Furthermore, we are excited to announce our partnership with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact [email protected] 866.299.8998 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
18-07-2025
- Health
- Business Upturn
Advancing Preventive Vascular Inflammation in the South with SmartVascular Dx™ Test
IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) — MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests that address unmet clinical needs, is proud to announce the expansion of the SmartVascular Dx™ test (formally known as the PULS™ Cardiac Test) into southern states. We are excited to announce that we are now officially included in the Medicare fee schedule, which allows us to offer our national medical coverage. Furthermore, our strategic partnerships with Buckeye Health Plan and America's Choice Provider Network have enabled significant expansion, ensuring that our groundbreaking test is accessible to patients across the entire region. The SmartVascular Dx test plays a vital role in the early identification of endothelial inflammation—a key indicator of vascular risk. With rates of vascular disease climbing in the southern population, this innovative tool empowers healthcare providers to proactively manage risk factors, paving the way for better health outcomes. 'We are excited to provide physicians in the South with a powerful tool to help them identify and manage vascular risks early on,' said Brennan Burns, Vice President of Policy & Payor Relations. 'By incorporating the SmartVascular Dx test into their clinical offerings, providers can play a critical role in driving down the prevalence of vascular diseases in the region.' We invite physicians across the southern states to reach out to MorningStar Laboratories to learn more about how they can implement the SmartVascular Dx test in their practice and contribute to advancing preventive cardiology in their communities. For additional information, inquiries, and implementation details, please contact MorningStar Laboratories directly or call us at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, and imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact [email protected] 866.299.8998 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
25-06-2025
- Health
- Yahoo
SmartVascular Dx™ Test: Enhancing Vascular Care in the Midwest
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., ('MSL' or 'the Company'), is a leading developer of precision diagnostic tests that address unmet clinical needs, is proud to announce its expansion in the Midwest with the introduction of the SmartVascular Dx™ test (formally known as the PULS™ Cardiac Test), a groundbreaking tool designed to improve vascular health outcomes. We are thrilled to announce that we are now officially included in the Medicare fee schedule, enabling us to offer national medical coverage. This effort reinforces our dedication to enhancing patient care and improving health outcomes in the region. As part of our commitment to improving patient care, MorningStar Laboratories has forged new partnerships with UnityPoint Health and the Advantage Benefits Team. This initiative aims to significantly increase access to innovative vascular services for patients throughout the Midwest. The SmartVascular Dx test stands at the forefront of preventative healthcare, enabling the early detection of vascular inflammation before clinical symptoms arise. This is especially crucial in the Midwest, where the prevalence of vascular disease presents a major public health challenge. By identifying potential issues earlier, we aim to empower healthcare providers to implement timely interventions that can save lives. 'We believe that early detection is key to effective treatment,' said Susie Lu, Chief Operating Officer & Director at MorningStar Laboratories. 'With the SmartVascular Dx test, we are empowering our physicians to intervene before serious health issues arise, ensuring better care for their patients.' We invite Midwest physicians to learn more about the SmartVascular Dx test and how it can be integrated into their practices. For additional information about the SmartVascular Dx test or to schedule a consultation, please contact MorningStar Laboratories at 949.267.7875 or visit Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar LaboratoriesMorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. Forward-Looking StatementsForward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contactmjjohnson@ 866.299.8998Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-06-2025
- Health
- Yahoo
SmartVascular™ Test: Revolutionizing Vascular Risk Assessment Nationwide
IRVINE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC ('MSL' or 'the Company'), a leading developer of precision diagnostic tests that address unmet clinical needs, proudly announces its SmartVascular Dx™ (SVDx) test (formally known as the PULS Cardiac test), designed to transform the early detection and management of vascular health, empowering healthcare providers to implement proactive strategies that significantly enhance patient outcomes. Vascular disease continues to be a leading cause of morbidity and mortality worldwide. The SVDx test leverages state-of-the-art technology to provide comprehensive insights into a patient's vascular health, allowing for earlier intervention and a more personalized care plan. By identifying at-risk individuals through advanced biomarkers, healthcare professionals can initiate preventative measures before critical health issues arise. 'Today marks a significant advancement in how we approach vascular and inflammatory health,' said Lawrence Dentice, President, Chief Commercial Officer & Director, MorningStar Laboratories. 'The SmartVascular Dx test is not just a diagnostic tool; it's a powerful resource for clinicians aimed at redefining our response to vascular risk. We believe early detection and tailored treatment can save lives.' Clinical EfficacyThe SmartVascular Dx test combines 7 protein biomarkers with 4 clinical factors, demonstrating a high accuracy rate in identifying potential arterial injury due to inflammation. This innovative approach enhances early detection capabilities, empowering healthcare providers to intervene sooner and improve patient outcomes. As has already been demonstrated in over 200,000 tests. Recent DevelopmentsIn a significant milestone, MorningStar Laboratories (MSL) has secured licensure in New York State, a recognition of its adherence to stringent laboratory standards. This achievement further affirms the quality and reliability of the SmartVascular Dx test, making it a trusted resource for healthcare professionals. We encourage physicians to contact MorningStar Laboratories to establish new accounts and integrate the SVDx test into their patient care protocols. By adopting this advanced diagnostic tool, healthcare providers can enhance preventive care strategies and better manage vascular health risks for their patients. For more information about the test and partnership opportunities, please visit us at or contact us at 866.299.8998. About MorningStar LaboratoriesMorningStar Laboratories ('MSL') is a specialty diagnostics development platform company that develops, manufactures, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, and imaging, to address the most challenging clinical problems. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services based on Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit SHDx at Twitter, Facebook, and LinkedIn. Forward-Looking StatementsForward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media ContactMary Jane JohnsonTel: 866.299.8998Mjjohnson@ Source: MorningStar Laboratories, LLC
